NEW YORK (GenomeWeb) – Edico Genome said today that it has made an agreement with Dell EMC to offer a bundled compute and storage solution for rapid, cost-effective, and accurate analysis of next-generation sequencing data.
Available now, the combined product includes Edico Genome’s Dragen bioinformatics processor integrated into a 1U Dell 4130 server for genome analysis, as well as Dell EMC’s Isilon scale-out networked attached storage for genomic data storage across all levels of throughput capacity.
Dragen offers users optimized hardware-based algorithms for genome mapping, alignment, sorting, and variant calling. It includes multiple clinical-grade pipelines such as genome/exome, transcriptome/RNA-seq, epigenome/methyl-seq, and metagenome/microbiome, which users can customize or add to their own custom algorithms.
According to Edico, the newest combination with the Dell EMC resources will allow users to implement Dragen more simply, reducing storage costs and speeding up analysis without compromising accuracy.
Customers have three tiers to choose from based on throughput needs, the company said. The small tier, for up to 100 terabytes, is most applicable to things like hospital-based sequencing efforts like those at pediatric or neonatal care units. The medium tier, between 100 terabytes and 250 terabytes, is more geared toward academic genomic centers and scientists in areas with large data demands. The large tier, from 250 terabytes to 1 petabyte, allow for management of data throughput for things like Illumina HiSeq X Ten systems at major sequencing centers.
The company did not disclose pricing for these three options.
"We believe our high-performance computing, storage, and cloud platforms, combined with Edico Genome’s next-generation sequencing bio-IT processor, Dragen, provides increased speed and accuracy and will accelerate time to insight for healthcare and life science organizations," Dell EMC general manager David DeAngelis said in a statement.
"Accelerating time to answers can lead to faster diagnoses for critically ill newborns, cancer patients and expecting parents waiting on prenatal tests, and allows scientists and drug developers to spend less time waiting for data and more time interpreting results," Edico Genome CEO Pieter van Rooyen added.
Edico has also recently announced several other deals combining Dragen with other computing resources — a deal with Amazon Web Services to make Dragen bioinformatics available on new Amazon cloud-based instances, another with Intel to integrate the Dragen platform with Intel processors, and a partnership with IBM to make Dragen available on one of IBM's high-performance computing servers.